L. Breton

Cell-Delivered Entry Inhibitors for HIV-1: CCR5 Downregulation and Blocking Virus/Membrane Fusion in Defending the Host Cell Population.

H. Kiem, J. Bartlett, G. Symonds, 2016, AIDS patient care and STDs.

Engineering Cellular Resistance to HIV-1 Infection In Vivo Using a Dual Therapeutic Lentiviral Vector.

I. Chen, J. Bartlett, D. An, 2015, Molecular therapy. Nucleic acids.

Preclinical safety and efficacy of an anti–HIV-1 lentiviral vector containing a short hairpin RNA to CCR5 and the C46 fusion inhibitor

K. Cornetta, I. Chen, J. Bartlett, 2014, Molecular therapy. Methods & clinical development.

CCR5 as a Natural and Modulated Target for Inhibition of HIV

J. Bartlett, G. Hütter, G. Symonds, 2013, Viruses.

The use of cell-delivered gene therapy for the treatment of HIV/AIDS

G. Symonds, M. Boyd, H. Johnstone, 2010, Immunologic research.

Geoff P. SymondsHelen A. JohnstoneMichelle L. Millington • Maureen P. BoydBryan P. BurkeLouis R. Breton

G. Symonds, M. Boyd, H. Johnstone, 2010 .

Engineering Cellular Resistance to HIV-1 Infection In Vivo Using a Dual Therapeutic Lentiviral Vector.

I. Chen, J. Bartlett, D. An, 2015, Molecular therapy. Nucleic acids.